B+
Bull case
25%
Probability
Target price
$1.35
+14.4% vs current
GDTC
CytoMed TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+1Most likely
B
Base case
45%
Probability
Target price
$0.95
-19.5% vs current
B-
Bear case
30%
Probability
Target price
$0.50
-57.6% vs current
AI sentiment snapshot
Latest data as of 2026-05-04
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+28.7
Score
AI commentary
Primary-source confirmation improved from none to limited: I confirmed the March 31, 2026 6-K/full-year update, the January 28, 2026 press release rebutting misleading claims, and the April 14, 2026 AGM materials. I did not find a separate company source confirming a fresh May 4, 2026 earnings release, and there was no usable analyst revision tape in the checked evidence. Price was about US$0.997 on May 4, 2026 versus the May 1 anchor of US$0.9735, but volume looked thin and that move is too small to treat as a decisive earnings reaction. Net: monitoring tone, not a strong directional call.
RankAlpha Sentiment Codex - 2026-05-04
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-22catalystPost-results runway scrutiny and May 22 AGM financing authorityHigh impact
The March 31, 2026 company filing showed cash and bank balances of US$1.63 million at December 31, 2025, down from US$3.87 million a year earlier, while the April 14, 2026 AGM materials ask shareholders to authorize issuance of new ordinary shares for follow-on offerings. That combination keeps financing optionality alive but raises near-term dilution sensitivity after the FY2025 update [#6K-2026-03-31] [#IR-2026-04-14].
2026-06-30eventMalaysia IND submission target before June 2026High impact
Management said on March 31, 2026 that it targets submitting an Investigational New Drug application in Malaysia before June 2026 for the unmodified gamma delta T-cell CTM-GDT study tied to Universiti Malaya. A confirmed filing or timeline slip would be a material binary for a micro-cap name with limited other near-term proof points [#6K-2026-03-31].
2026-12-31catalystANGELICA Phase I dose-escalation progress and 2026 completion targetHigh impact
The same March 31, 2026 filing said the first-in-human ANGELICA CAR-T Phase I trial in Singapore had treated six patients across two dose levels, was moving toward dose level 3, and was targeted for completion in 2026. Clean progression on dose escalation would matter more than generic quarterly reporting because the equity value is still largely milestone-driven [#6K-2026-03-31].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-04 • Updated nightlySource: Internal modelMethodology